Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 4:01 PM ESTFull Year UDENYCA® Sales of $356.1 Million
Full Year Cash Flow from Operating Activities of $28.4 million
REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019.Â
Fourth Quarter 2019 and Recent Corporate Highlights
Coherus commercial capabilities advanced its core mission to expand choice, improve patient access and lower healthcare costs in the United States:
UDENYCA® (pegfilgrastim-cbqv) launch continues to deliver... More